Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

An Australian medical technology company, Proteomics International, has published a study demonstrating a new blood test ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...